Dual renin-angiotensin system blockade: In patients with single functioning kidney and proteinuria

European Journal of Internal Medicine

Volumn 20, Issue 2, 2009, Pages 186-189

  Robles, N R ^a   Ruiz Jimenez B ^a   Hernandez Gallego R ^a   Ruiz Calero, R ^a   Sanchez Casado E ^a   Cubero, J J ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Dual blockade; Renin angiotensin system; Single functioning kidney

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LOSARTAN; PERINDOPRIL; POTASSIUM; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEPHRECTOMY; POTASSIUM; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 62649109883     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.06.002     Document Type: Article

References (21)

1. Kasiske B.L., Ma J.Z., Louis T.A., and Swan S.K. Long-term effects of reduced renal mass in humans. Kidney Int 48 (1995) 814-819
2. Russo D., Minutolo R., Pisani A., Esposito R., Signorello G., Andreucci M., et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nefropathy. Am J Kidney Dis 38 (2001) 18-25
3. Ruilope L.M., Aldigier J.C., Ponticelli C., Oddou-Stock P., Botteri F., and Mann J.F. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18 (2000) 89-95
4. Luño J., Barrio V., Goicoechea M.A., Gonzalez C., Garcia de Vinuesa S., Gomez F., et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 62 Suppl. 82 (2002) S47-S52
5. Jacobsen P., Andersen S., Rossing K., Hansen B.V., and Parving H.H. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17 (2002) 1019-1024
6. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., et al. Randomised controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321 (2000) 1440-1444
7. Nakao N., Yoshimura A., Morita M., Kayano T., and Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361 (2003) 117-124
8. Reardon L.C., and Macpherson D.S. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?. Arch Intern Med 158 (1998) 26-32
9. Palmer F.B. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351 (2004) 585-592
10. Mangrum A.J., and Bakris G.L. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol 24 (2004) 168-175
11. Robles NR, Cancho B, Barroso S, Martin MV, Sanchez Casado E. Untoward effects of dual renin-angiotensin system blockade: influence of previous chronic renal failure. Intl J Clin Pract. (In press).
12. The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560-72, 2003.
13. Brenner B.M. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23 (1983) 647-655
14. Wade V.L., and Gleason B. Dual Blockade of the renin-angiotensin system in diabetic nephropathy. Ann Pharmacother 38 (2004) 1278-1282
15. Ferrari P., Marti H.P., Pfister M., and Frey F.J. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens. 20 (2002) 125-131
16. Kincaid-Smith P., Fairley K., and Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal failure and proteinuria. Nephrol Dial Transplant 17 (2002) 597-601
17. Berger E.D., Bader B.D., Ebert C., Risler T., and Erley C.M. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 20 (2002) 739-743
18. Laverman G.D., Navis G., Henning R.H., de Jong P.E., and de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62 (2002) 1020-1025
19. Ichikawa I. Will angiotensin II receptors blockers be renoprotectives in humans?. Kidney Int. 50 (1996) 684-692
20. Brunner H.R. ACE inhibitors in renal disease. Kidney Int. 42 (1992) 463-479
21. Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., et al. On behalf of Elite Study (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 (1997) 747-752